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Abstract
Background: The integration of HR-HPV genome into host DNA is regarded as a key step for the development of
cervical cancer. However, HR-HPV genome indeed exists as episome except for integrant. It may be alternative
mechanisms in episome-associated carcinogenesis, although, by which HPV 16 episome induces cervical
carcinogenesis is unclear now.
Methods: Ninety-three invasive cervical cancer tissues with HPV16 positive were collected. Viral physical status was
calculated from comparing E2 to E6-copies and detection of viral load was made with realtime-PCR using copy
numbers of E6. HPV16 E6 mRNA transcript levels were measured by realtime-PCR. The methylation frequency of
HPV16 promoter was detected by PCR and pyrosequencing.
Results: In 93 samples, 21.5% (20/93) presented purely integrated viral genome, 53.8% (50/93) mixed viral genome,
and 24.7% (23/93) purely episomal viral genome. Mean E6 expression in samples with purely episomal viral
genomes was 7.13-fold higher than that with purely integrated viral genomes. Meanwhile, viral load in samples
with purely episomal viral genomes was 4.53-fold higher than that with purely integrated viral genomes. E6 mRNA
expression increased with the viral load in purely episomal cases. There were no differences of mean methylation
frequency between purely episomal and integrated virus and among five CpG positions of HPV16 promoter for all
samples. And there also was no correlation between E6 mRNA expression and methylation of HPV16 promoter
among all samples with purely HPV16 episomal virus.
Conclusions: HPV16 with the purely episomal viral genomes exists in a definite proportion of invasive cervical
cancer, and episomal HPV16 also overexpresses E6 mRNA, probably through a high level of viral load.
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Background
Cervical cancer is one of the most common cancers among
women worldwide. Infection with high-risk human papillo-
maviruses (HPV) is a causal factor for cervical intraepithe-
lial neoplasia and cervical cancer. Among all the HR-HPV
genotypes, HPV 16 is the most prevalent, reaching 65.2%
of all genotypes in cervical cancer [1]. Human papillomavi-
rus (HPV) genome integration into the host chromosome
is considered as a crucial event during the life cycle of the
virus and a major step towards carcinogenesis [2]. The
integration of HPV16 DNA promotes a constitutive high
expression level of E6 and E7 oncoproteins, resulting in
the extensive proliferation of the infected epithelial cells.
Typical integrants have complete or partial disruption of
the open reading frame (ORF) in E2 ORF [3]. An import-
ant consequence of viral integration is an abolishment of
E2 gene inhibiting the expression of oncogene E6 and E7,
resulting in the extensive proliferation and malignant
transformation of infected epithelial cells. Higher steady-
state levels of viral oncogene transcripts in precancers and
invasive cancers were expected as a consequence of virus
integration. Thus, the integration of HR-HPV genome into
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host DNA is regarded as a key, even prerequisite, step for
the development of cervical cancer.
However, the actual physical status of HPV 16 genome
in cervical cancer cells appears far more complicated.
For instance, Li et al. [4] reported the existence of HPV
16 integration in all of 15 cases of cervical cancer tis-
sues, but Dutta S et al. [5] detected 82% cases contained
HPV16 integrant in cervical cancer samples, and
Mazumder D and his collogues found that 70.3% sam-
ples harbored integration HPV16 in cervical cancer tis-
sue [6]. Further, Vinokurova and collaborators found
that as high as 45% samples contained purely episomal
virus in HPV16-positive cervical cancer tissues [7], and
Cheung et al. [8] found pure episomal HPV16 genomes
in 14 of 29 (48.3%) cervical cancer tissues. Therefore,
HR-HPV genome indeed exists as episome except for in-
tegrant. This phenomenon points toward the biological
plausibility of cervical carcinogenesis under the impact
of HPV16 episome, in addition to E2 disruption due to
viral genome integration into the host genome. It may
be alternative mechanisms in episome-associated car-
cinogenesis, although, by which HPV 16 episome in-
duces cervical carcinogenesis is unclear now.
Here, we detected HPV16 physical status, E6 mRNA
transcript level, viral load, and E6 promoter methylation
in HPV16 positive invasive cervical cancer tissues, and an-
alyzed the association of HPV16 E6 expression with viral
load and promoter methylation. The aim of the study was
to understand the potential mechanism in cervical cancer
pathogenesis with HPV16 episome infection.
Methods
Tissue sample collection
A total of 93 biopsied cervical cancer tissues were ob-
tained from female patients (range 23–71 years, median
39 years) treated at the Department of Gynecology On-
cology, Women’s Hospital, School of Medicine, Zhejiang
University, China. All samples were histology-confirmed
as invasive cervical cancer and had been confirmed to
HPV16 infection by type specific PCR. Eighty-four cases
of squamous cancer, three of adenosquamous cancer
and six of adenocarcinoma were included. Two cases
were stage IA1, 66 stage IB1, 13 stage IB2, ten stage IIA
and two stage IIB. The study was done in accordance
with the guidelines of the local ethical committee.
DNA extraction, RNA extraction and reverse transcription
Biopsy tissues were physically disrupted by magnetic
beads. DNA was extracted using UniversalGen DNA Kit
(Cowin Biotech, Beijing, China) and stored at −80 °C
until use. Total RNAs were extracted with TRIZOL re-
agent (Invitrogen Carlsbad, CA, USA) following manu-
facturer's instructions. cDNA was synthesized with
PrimeScriptTM RT Master Mix (TaKaRa Otsu, Shiga,
Japan) and stored at −80 °C until use.
Detection of HPV16 physical status
To determine the physical status of the virus, E2 and E6
gene of HPV 16 DNA were quantified and the E2/E6 ra-
tio was calculated. This approach is based on the fact
that episomes present an identical amount of E2 and E6,
whereas integration induces loss of E2.
Detection of E2 and E6 gene for HPV16 was performed
with real-time PCR on the 7900HT Fast Real-Time PCR
System. Standard curves for E2 and E6 gene were estab-
lished by making a serial dilution of the plasmid pBR322
containing the total HPV16 genome. Dilutions were made
to equal 50, 500, 5000, 50 000, 500 000 and 5000 000 cop-
ies of HPV16 E2 and E6. The sequence information of
each primers used [9] (HPV16 E2F and E2R, HPV16 E6F
and E6R) are available in Table 1. Samples were analyzed
in triplicates and at least three no-template control reac-
tion mixtures were included in each trial. After an initial
denaturation at 95 °C for 15 s, reaction mixtures under-
went 40 cycles at 95 °C for 5 s followed by 60 °C for 30 s.
Results were analyzed by software 7900HT Fast System
SDS Software. A ratio of ≥1 indicated pure episomal form,
“0” indicated integration and a value bellow 1 indicated
the presence of mixed infection of both integrated and
episomal forms.
Detection of HPV16 viral load
The strategy involved the measurement of the total viral
load of HPV16 DNA by quantification of the HPV16 E6
gene and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) with real-time PCR. The sequence informa-
tion of GAPDH DNA primers (GAPDH-DF and
GAPDH-DR) [10] were seen in Table 1. Standard curves
for GPADH was obtained by amplification of a 2-fold di-
lution series of female human DNA between 112.5 and
1.75 ng/μL (Promega).
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The amount of genomic DNA (ng) presented in each
sample was divided by the weight of 1 genome equivalent
(6.6 pg/cell) to obtain the number of cells in the sample
[9]. Viral load was expressed as the copies of E6 per cell.
Detection of E6 mRNA transcripts
E6 mRNA transcript expression was quantified by using
the same primer. Human Endogenous Control GAPDH
(GAPDH-cDF and GAPDH-cDR) was used as normalizer,
listed in Table 1. Real-time PCR was detected under the
same conditions with an initial denaturation at 95 °C for
15 s, reaction mixtures underwent 40 cycles at 95 °C for
5 s and followed by 60 °C for 30 s. Samples were also ana-
lyzed in triplicates in each trial.
Detection the methylation frequency of HPV16 promoter
The Methylation frequency of HPV16 promoter was de-
tected with PCR and pyrosequencing. The promoter P97 of
HPV 16 contains potential methylation sites with five CpG
dinucleotides located at 31, 37, 43, 52 and 58 nt (reference
sequence NC_001526). Samples were treated with bisulphite
using EZ DNA Methylation-Gold Kit according to manufac-
turer’s instructions (ZYMO Research, Irvine, USA).
HPV16MP-F and HPV16MP-Rbio primers (Seen in Table 1)
were used in PCR [11]. PCR conditions were as follows: pre-
heating at 94 °C for 5 min, 40 cycles at 94 °C for 45 s, 55 °C
for 45 s, 72 °C for 45 s, and a final extension at 72 °C for
10 min. One of the primers was labeled with 5-biotin. Then
PCR amplifiers were detected by pyrosequencing with the
primer HPV16MP-S. Samples were prepared for pyrose-
quencing using the Vacuum prep Workstation (Qiagen).
Single-strand sequencing template was transferred to a 96-
well sequencing plate containing sequencing primer
HPV16MP-S (Seen in Table 1). The plate was incubated in
85 °C for 2 min. Pyrosequencing was performed in a PSQ
96 MA system using PyroMark Q96 Reagents (Qiagen).
The results were analyzed in the Pyro Q-CpG Software to
determine the proportion of C/T at the targeted position(s).
Methylated samples were further divided into different
methylation degree groups of highly methylated (>50%),
medium methylated (11–50%) and low methylated (<10%).
Statistical analysis
Data were analyzed with independent-samples t-test,
Mann–Whitney test, Kruskal–Wallis test and Chi-
Square test using IBM SPSS statistics 20. All P-values
less than 0.05 were considered statistically significant.
All reported P-values were bilateral.
Results
Physical status of HPV16 in invasive cervical cancer
tissues
The physical status of all three forms (episomal, inte-
grated and mixed) in HPV16 genome was analyzed in 93
invasive cervical cancer samples (Fig. 1). In detail, 21.5%
(20/93) presented E2/E6 ratios of “0” and were regarded
as complete integrated viral genome, 53.8% (50/93) pre-
sented ratios between “0-1” and regarded as mixed viral
DNA, and 24.7% (23/93) presented ratios of “≥1” and
regarded as purely episomal status.
The expression of E6 mRNA and viral loads in different
physical status from invasive cervical cancer tissues
We quantified E6 expression (normalized by GAPDH)
by qRT-PCR of cDNA products generated directly from
mRNA. Relative quantification based on comparative CT
method revealed the significant difference (P = 0.003;
Kruskal-Wallis H test) among ΔCT (E6 CT - GPADH
CT) values of cases with integrated viral genome (mean
ΔCT = 3.28), mixed viral genome (mean ΔCT = 2.27)
and episomal viral genome (mean ΔCT = 0.45). The
fold-change analysis (using 2-ΔΔCT, where ΔΔCT =mean
ΔCT of purely episomal - mean ΔCT of purely inte-
grated), depicted that E6 expression in cases with purely
episomal viral genomes was 7.13 folds higher than that
in cases with purely integrated viral genomes.
Viral load in the 93 samples varied between 0.85 and
1350.48 copies per cell with a median value of 18.60 cop-
ies per cell. Fig. 2 showed the distribution of viral load
with respect to genome physical status. Mean viral load
levels of HPV 16 were 52.56 copies per cell among inte-
gration form, 113.65 copies per cell among mixed form,
and 238.31 copies per cell among episomal form. Viral
copy numbers per cell were significantly higher (P =0.002;
Fig. 1 The physical status of three forms (episomal, integrated and
mixed) in HPV16 genome was analyzed in 93 invasive cervical
cancer samples. Of those, 21.5% presented complete integrated,
53.8% mixed, and 24.7% purely episomal viral genome, respectively
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Kruskal-Wallis H test) among the episomal cases (mean
238.31 copies per cell) compared to the mixed cases
(mean 113.65 copies per cell) and the purely integrated
cases (mean 52.56 copies per cell). Viral load in cases with
purely episomal viral genome was 4.53-fold more than
that in cases with purely integrated viral genome.
Samples were further divided into two groups of high
viral load group (≧50copies/cell) and low viral load
group (<50copies/cell) on the basis of viral load. E6
mRNA expression was higher in high viral load group
than that in low viral load group in purely episomal
cases (P = 0.007; Mann–Whitney Test), but E6 mRNA
expression was not significantly different between high
and low viral load group in purely integrated cases.
E6 mRNA expression and the methylation of HPV16
promoter from invasive cervical cancer tissues
Bisulfite modification and pyrosequencing were used to
detect the five CpG methylation status of HPV 16 pro-
moter (31 nt, 37 nt, 43 nt, 52 nt and 58 nt) in invasive
cervical cancer tissues (Fig. 3). Out of 93 cases, examin-
ation of the promoter regions was unsuccessful in 3
cases, which were excluded from the statistical analysis.
Therefore, 90 samples were analyzed for the methylation
status of HPV 16 promoter, including 20 cases with
purely integrated virus, 49 cases with mixed virus, and
21 cases with purely episomal virus.
Mean methylation frequencies of the integrated, mixed
and episomal virus were 20.2, 25.3, and 17.0%, respectively,
Fig. 2 Mean viral load level of HPV 16 was 52.56 copies per cell with integration form, 113.65 copies per cell with mixed form, and 238.31 copies
per cell with episomal form, respectively. Kruskal-Wallis H test showed that viral copy numbers per cell with episomal form were significantly
higher than that with mixed form and purely integrated form (P = 0.002)
Fig. 3 The promoter of HPV 16 E6 contains methylation sites with five CpGs dinucleotides located at 31 nt, 37 nt, 43 nt, 52 nt and 58 nt. After
genomic DNA is treated with sodium bisulphate, T represents unmethylated C and C represents methylated C. The proportion of C represents
the methylation frequency in the CpG dinucleotides. In this representative sequence, the methylation frequencies of the five CpGs at 31 nt, 37 nt,
43 nt, 52 nt and 58 nt were 20, 16, 14, 20, and 19%, respectively
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at the 31 nt CpG; 21.5, 26.1, and 17.5%, respectively, at the
37 nt CpG; 22.1, 27.8, and 18.6%, respectively, at the 43 nt;
22.1, 28.0, and 19.3%, respectively, at the 52 nt CpG; 22.7,
28.8, and 20.5%, respectively, at the 58 nt CpG in HPV16
promoter. There were no differences of mean methylation
frequency among the five CpG positions of HPV16 pro-
moter for all cases (P > 0.05; Kruskal-Wallis H test), as
shown in Fig. 4. Furthermore, there was no significant dif-
ference of promoter methylation frequency between purely
episomal virus and purely integrated virus (P > 0.05;
Kruskal-Wallis H test).
Methylation frequency also was calculated from all five
positions in the promoter as an average. In 90 invasive
cervical cancer samples, 15.6% (14/90) were high meth-
ylated, 41.1% (37/90) were medium methylated, and
43.3% (39/90) were low methylated. No CpGs in the
promoter had a methylation frequency of 100% in all in-
vasive cervical cancer tissues. The proportions of highly,
medium, and low methylated were 10, 40, and 50%, re-
spectively, in the invasive cervical cancer tissues with in-
tegrated HPV16, while the proportions of these were
22.4, 42.9, and 34.7, respectively, with mixed HPV16,
and 4.8, 38.1 and 57.1%, respectively, with episomal
HPV16. The proportions of highly, medium, and low
methylated HPV16 promoter were not significantly dif-
ferent between purely episomal virus and purely inte-
grated virus, as shown in Fig. 5.
The correlation between the expression of E6 mRNA
and methylation of HPV16 promoter was investigated.
There were no differences in E6 mRNA expression
among different methylation degrees of promoter in all
90 cases of invasive cervical cancer tissues. And there
also was no correlation between E6 mRNA expression
and methylation of HPV16 promoter among all samples
with purely HPV16 episomal virus.
Discussion
When high-risk human papillomavirus infects host cells,
some of viral genomes integrated into host genome. As
a consequence, deregulated expression of the HPV E6
and E7 genes in epithelial stem cells leads to malignant
transformation in the respective cells at early stages of
dysplasia. Integration of viral genome into the host gen-
ome, chiefly at fragile sites [2, 12], is considered as a crit-
ical event in the pathogenesis of cervical neoplasia due
to the loss of negative feedback control of oncogene ex-
pression from viral itself through E2 disruption [13, 14].
In addition to viral oncogene over-expression, integrated
HPV also may be regarded as a selectable form of the
virus because this form not only is resistant to clearance
from host, but also enables infected cells to maintain
viral oncogene expression and avoids cell death [15].
However, HPV 16 also can exist as episome in clinical
invasive cervical cancer tissues actually. Our results
showed that a substantial proportion of invasive cervical
cancer cases (24.7%) contained purely episomal viral
genome, only 21.5% of invasive cervical cancer samples
contained fully integrated genome, and 53.8% of samples
had a mixed genome (integrated and episomal viral gen-
ome). Our study identified that a substantial proportion
of individuals of invasive cervical cancer carried epi-
somal virus, in line with previous studies [5, 8, 16].
Thus, our study suggest, together with other studies [8],
that purely episomal viral genome can exist in invasive
cervical cancer and integration is not a prerequisite step
for invasive cervical cancer development.
Fig. 4 HPV 16 contains methylation sites with five CpG dinucleotides located at 31 nt, 37 nt, 43 nt, 52 nt and 58 nt. Methylation frequencies of
the integrated, mixed and episomal virus were shown in the figure. There are no differences of mean methylation frequency among five CpG
positions of HPV16 promoter
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It is known that high levels of the viral oncoproteins
E6 and E7 in proliferating cells of epithelia are a neces-
sity for oncogenic transformation. Up-regulation of E6/
E7 expression also is constitutively required to maintain
the transformed phenotype of invasive cervical cancer
regardless of integration or episome status [8]. An in
vitro experiment has revealed similarities between the
episome and integrant associated routes of neoplastic
progression [17]. Some reports have also showed that in-
tegration of the HPV16 genome does not invariably re-
sult in high levels of viral oncogene transcripts [18], and
HR-HPV integration per se dose not necessarily lead to
increased oncogene expression [17]. Our study found
that purely episomal viral genome of HPV 16 in invasive
cancer tissues also had E6 mRNA overexpression, which
even higher than that of integrated virus, suggesting that
HPV oncogenes are also overexpressed in invasive cer-
vical cancer with viral episomal infection, but the mech-
anism may be involved in a way other than viral
integration and E2 disruption.
It has been shown that viral load is one of the risk fac-
tors in invasive cervical cancer development [19]. There-
fore, we detected viral load in different viral physical
status. In our study, purely HPV 16 episome contained
238.31 copies per cell in invasive cervical cancer tissues,
but purely integrated HPV 16 contained only 52.56 copies
per cell. Mean viral load in cases with purely episomal
viral genomes was 4.53-fold compared with purely inte-
grated viral genomes. We further analyzed viral load and
E6 mRNA transcript levels of HPV16 in different viral
physical status, and found that mean E6 expression in
cases harboring purely episomal viral genomes was 7.13-
fold higher than those harboring purely integrated forms.
Furthermore, our result showed that E6 mRNA expres-
sion increased simultaneously with the viral loads in HPV
16 episomal genomes, but not in HPV 16 integrated ge-
nomes. Similarly, Marongiu L and his collogues previously
found that samples harboring solely episomal HPV16
DNA had a higher viral load than samples with solely inte-
grated forms [20]. Thus, our and previously findings sug-
gest that the overexpression of HPV oncogene may be
mediated through a high viral load under HPV episomal
status without E2 disruption [19]. In fact, intact E2 protein
can enhance viral DNA replication by interacting with the
viral replication factor E1 and recruiting it to the origin of
replication [21, 22], and consequently facilitates viral
genome segregation by tethering the viral genomes to host
mitotic chromosomes [23].
Gene expression is influenced by promoter DNA
methylation. HPV 16 E6 and E7 genes are transcribed
from the promoter P97. The promoter P97 region con-
tains several binding sites for cellular transcription fac-
tors, such as Sp1, TFIID, and E2BS. DNA methylation
within the binding sites of transcription factors, such as
Sp1, might block binding indirectly, either by changing
the conformation of chromatin or by interacting with
methyl-CpG-specific repressor proteins [24]. The cap-
acity of the full-length E2 ORF gene product E2 to bind
Fig. 5 Methylation frequency is calculated from all five positions in the promoter as an average. >50% of methylation frequency is regarded as
high methylated, 11–50% as medium methylated and <10% as low methylated. The proportions of highly, medium, and low methylation are
shown in invasive cervical cancer tissues with integrated, mixed and episomal HPV16
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E2BSs in vitro is inhibited by methylation of cytosines
within its binding site [25]. It is known that the inter-
action of E2 with various E2BSs mediates repression or
activation of transcription and, through its interaction
with E1, viral DNA replication [26]. However to date,
few studies have examined the E6 mRNA transcript
levels with respect to the promoter methylation of
HPV16 in clinical invasive cervical tissues. Cheung JL
and his collogues found that higher proportion of sam-
ples harboring the pure episomal form had high-level
methylation at the 4 CpGs of two E2BSs in the pro-
moter, compared to those of integrated forms (including
mixed forms) [8]. However, our study did not find the
differences in E6 mRNA expression between purely epi-
somal and integrated virus and among different methyla-
tion degrees of promoter in the cases that containing
purely HPV16 episomal virus. Thus, the impact of HPV
promoter methylation on viral ocogene expression ap-
pears to be limited, but a further investigation with lar-
ger samples is needed.
Conclusion
In summary, we found that HPV16 with the purely epi-
somal viral genomes exists in a definite proportion of
invasive cervical cancer, and episomal HPV16 also over-
expresses E6 mRNA, probably through a high level of
viral load. The impact of HPV16 E6/E7 promoter methy-
lation on E6 expression may be limited in invasive cer-
vical cancer with episomal HPV16 infection. Our results
may provide another mechanism by which HR-HPV
with episomal viral genomes induces the development of
cervical cancer.
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